However, while HER2-targeted treatments also show promise in the setting of metastasis[7], outcomes in metastatic disease have not improved significantly over the last several years[7,8] and only about 30% of stage 4 breast cancers are HER2+[4] and thus amenable to this therapy. The gene discussed is ERBB2; the disease is metastatic neoplasm.